Treatment strategies

C. Chiron, M. Duchowny

Research output: Contribution to journalArticle

Abstract

There has been important progress in the identification of antiepileptic compounds and their indications in children over the past 15 years: their number has doubled and specific pediatric trials are being performed to document their effect according to seizures and syndromes as well as their tolerability in pediatrics. The improved understanding of pharmacokinetics and drug-drug interactions has helped to optimize treatment. Specific issues specific of infants have also been studied although new antiepileptic drugs are still dramatically lacking for this age group.Before reaching a syndromic diagnosis, the choice of a first- line agent goes to compounds with the largest range of efficacy and least identified risks. Subsequent choices are mainly based on the epilepsy syndrome and seizure type in addition to good clinical practice to determine dose, adverse effect profile, risk of aggravating seizures and drug interactions, clinician's experience, cultural habits, and availability of drugs. If there are several options, preference is given to the compound that exhibits the best risk/benefit ratio, or the most rapid titration when seizure frequency is the major issue. For new antiepileptic compounds, price is often a limiting factor in countries with poor insurance coverage. Third generation anti-epileptic drugs are emerging which also seem to be promising.

Original languageEnglish
Pages (from-to)727-739
Number of pages13
JournalHandbook of Clinical Neurology
Volume111
DOIs
StatePublished - May 2 2013

Fingerprint

Seizures
Anticonvulsants
Drug Interactions
Pharmaceutical Preparations
Pediatrics
Insurance Coverage
Therapeutics
Habits
Epilepsy
Pharmacokinetics
Age Groups
Odds Ratio

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Treatment strategies. / Chiron, C.; Duchowny, M.

In: Handbook of Clinical Neurology, Vol. 111, 02.05.2013, p. 727-739.

Research output: Contribution to journalArticle

Chiron, C. ; Duchowny, M. / Treatment strategies. In: Handbook of Clinical Neurology. 2013 ; Vol. 111. pp. 727-739.
@article{ad7b1f823bff46b9a4d5fda469a445bd,
title = "Treatment strategies",
abstract = "There has been important progress in the identification of antiepileptic compounds and their indications in children over the past 15 years: their number has doubled and specific pediatric trials are being performed to document their effect according to seizures and syndromes as well as their tolerability in pediatrics. The improved understanding of pharmacokinetics and drug-drug interactions has helped to optimize treatment. Specific issues specific of infants have also been studied although new antiepileptic drugs are still dramatically lacking for this age group.Before reaching a syndromic diagnosis, the choice of a first- line agent goes to compounds with the largest range of efficacy and least identified risks. Subsequent choices are mainly based on the epilepsy syndrome and seizure type in addition to good clinical practice to determine dose, adverse effect profile, risk of aggravating seizures and drug interactions, clinician's experience, cultural habits, and availability of drugs. If there are several options, preference is given to the compound that exhibits the best risk/benefit ratio, or the most rapid titration when seizure frequency is the major issue. For new antiepileptic compounds, price is often a limiting factor in countries with poor insurance coverage. Third generation anti-epileptic drugs are emerging which also seem to be promising.",
author = "C. Chiron and M. Duchowny",
year = "2013",
month = "5",
day = "2",
doi = "10.1016/B978-0-444-52891-9.00075-0",
language = "English",
volume = "111",
pages = "727--739",
journal = "Handbook of Clinical Neurology",
issn = "0072-9752",
publisher = "Elsevier",

}

TY - JOUR

T1 - Treatment strategies

AU - Chiron, C.

AU - Duchowny, M.

PY - 2013/5/2

Y1 - 2013/5/2

N2 - There has been important progress in the identification of antiepileptic compounds and their indications in children over the past 15 years: their number has doubled and specific pediatric trials are being performed to document their effect according to seizures and syndromes as well as their tolerability in pediatrics. The improved understanding of pharmacokinetics and drug-drug interactions has helped to optimize treatment. Specific issues specific of infants have also been studied although new antiepileptic drugs are still dramatically lacking for this age group.Before reaching a syndromic diagnosis, the choice of a first- line agent goes to compounds with the largest range of efficacy and least identified risks. Subsequent choices are mainly based on the epilepsy syndrome and seizure type in addition to good clinical practice to determine dose, adverse effect profile, risk of aggravating seizures and drug interactions, clinician's experience, cultural habits, and availability of drugs. If there are several options, preference is given to the compound that exhibits the best risk/benefit ratio, or the most rapid titration when seizure frequency is the major issue. For new antiepileptic compounds, price is often a limiting factor in countries with poor insurance coverage. Third generation anti-epileptic drugs are emerging which also seem to be promising.

AB - There has been important progress in the identification of antiepileptic compounds and their indications in children over the past 15 years: their number has doubled and specific pediatric trials are being performed to document their effect according to seizures and syndromes as well as their tolerability in pediatrics. The improved understanding of pharmacokinetics and drug-drug interactions has helped to optimize treatment. Specific issues specific of infants have also been studied although new antiepileptic drugs are still dramatically lacking for this age group.Before reaching a syndromic diagnosis, the choice of a first- line agent goes to compounds with the largest range of efficacy and least identified risks. Subsequent choices are mainly based on the epilepsy syndrome and seizure type in addition to good clinical practice to determine dose, adverse effect profile, risk of aggravating seizures and drug interactions, clinician's experience, cultural habits, and availability of drugs. If there are several options, preference is given to the compound that exhibits the best risk/benefit ratio, or the most rapid titration when seizure frequency is the major issue. For new antiepileptic compounds, price is often a limiting factor in countries with poor insurance coverage. Third generation anti-epileptic drugs are emerging which also seem to be promising.

UR - http://www.scopus.com/inward/record.url?scp=84876799480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876799480&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-52891-9.00075-0

DO - 10.1016/B978-0-444-52891-9.00075-0

M3 - Article

C2 - 23622220

AN - SCOPUS:84876799480

VL - 111

SP - 727

EP - 739

JO - Handbook of Clinical Neurology

JF - Handbook of Clinical Neurology

SN - 0072-9752

ER -